semaglutide 4mg vial GLP-1 (S) Photo Illustration of the new

Introduction Once-weekly semaglutide 1 mg is a novel glucagon-like peptide 1 receptor agonist (GLP-1 RA) that, in the SUSTAIN clinical trials, has demonstrated greater reductions in glycated haemoglobin (HbA1c) and body weight than the other GLP-1 RAs exenatide extended-release (ER) 2 mg, dulaglutide 1.5 mg and liraglutide 1.2 mg

Their executive team and research and development council, along with a consortium of healthcare experts, work hard every day to make sure they are continually advancing client care

But as key patents begin approaching expiry over the coming years, a new phase is unfolding the generics and biosimilar race

Provider review documentation (eligibility assessment + provider summary note structure for chart consistency)

and Zepbound, authorized for weight loss

By May 2025, GLP-1s accounted for 52% of all diabetes prescription volume, up from just 18% in 2020